Compare Abeona Therapeutics Inc (ABEO) vs ProShares UltraPro Short QQQ ETF (SQQQ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs ProShares UltraPro Short QQQ ETF — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while ProShares UltraPro Short QQQ ETF trades at $40.53. The key difference: Abeona Therapeutics Inc is trading nearer its 52-week high, ProShares UltraPro Short QQQ ETF nearer its low. Which is the better fit depends on your goals.
| ABEO | SQQQ | |
|---|---|---|
Market Cap | $373.32M | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $7.23 | $97.65 |
52-Week Low | $4.17 | $36.31 |
Enterprise Value | $228.22M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
SQQQ (ProShares UltraPro Short QQQ ETF) declined 4.18% to $38.28, reflecting its bearish inverse leverage strategy against the Nasdaq-100. Technical indicators show a predominantly bearish signal with moving averages indicating strong selling pressure. The ETF's structure as a daily -3x leveraged product creates inherent decay risks, with historical data showing significant long-term value erosion. Recent news highlights concerns about SQQQ's suitability as a long-term investment vehicle.
SQQQ faces structural headwinds from daily reset mechanisms that compound losses in rising markets. While potentially useful for short-term tactical bearish bets, the ETF's design makes it unsuitable for buy-and-hold strategies. Investors seeking Nasdaq-100 exposure should consider the significant risks of value decay and timing sensitivity inherent in leveraged inverse products.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About ProShares UltraPro Short QQQ ETF
SQQQ is a leveraged inverse ETF that seeks daily investment results, before fees and expenses, that correspond to three times the inverse (-3x) of the daily performance of the Nasdaq-100 Index. It is a tactical trading tool designed for sophisticated investors to profit from or hedge against declines in large-cap technology and growth stocks. Due to its daily reset and the effects of compounding, it is intended for short-term use and carries significant risk if held during periods of high market volatility.
Read more on SQQQ →
